References
- Japanese Society of Allergology Asthma Guideline Committee. Guideline for Prevention and Management of Asthma 2021. Tokyo: Kyowa Kikaku; 2021.
- Nair P, Wenzel S, Rabe K, et al. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med. 2017;376(25):2448–2458. doi:10.1056/NEJMoa1703501
- Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343–373. doi:10.1183/09031936.00202013
- GINA Global initiative for asthma. Global strategy for asthma management and prevention; 2023. Available from: https://ginasthma.org/wp-content/uploads/2023/05/GINA-2023-Full-Report-2023-WMS.pdf. Accessed June 2, 2023.
- Nagase H, Adachi M, Matsunaga K, et al. Prevalence, disease burden, and treatment reality of patients with severe, uncontrolled asthma in Japan. Allergol Int. 2020;69(1):53–60. doi:10.1016/j.alit.2019.06.003
- Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371(13):1189–1197. doi:10.1056/NEJMoa1403291
- Rabe K, Nair P, Brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018;378(26):2475–2485. doi:10.1056/NEJMoa1804093
- Canonica GW, Rottoli P, Bucca C, et al. Improvement of patient-reported outcomes in severe allergic asthma by omalizumab treatment: the real life observational PROXIMA study. World Allergy Organ J. 2018;11(1):33. doi:10.1186/s40413-018-0214-3
- Wu P, Han Y, Chen T, Tu XM. Causal inference for Mann-Whitney-Wilcoxon rank sum and other nonparametric statistics. Stat Med. 2014;33(8):1261–1271. doi:10.1002/sim.6026
- Kimura H, Makita H, Taniguchi N, et al. Determination of the cutoff values of Th2 markers for the prediction of future exacerbation in severe asthma: an analysis from the Hokkaido Severe Asthma Cohort Study. Allergol Int. 2021;70(1):68–73. doi:10.1016/j.alit.2020.09.001
- Tanosaki T, Kabata H, Matsusaka M, et al. Clinical characteristics of patients with not well-controlled severe asthma in Japan: analysis of the Keio Severe Asthma Research Program in Japanese population (KEIO-SARP) registry. Allergol Int. 2021;70(1):61–67. doi:10.1016/j.alit.2020.06.002
- To Y, Taguchi Y, Shimazaki T, et al. Real-world treatment and health care resource use among severe asthma patients in Japan. Respir Investig. 2021;59(4):464–477. doi:10.1016/j.resinv.2021.02.010
- Agache I, Beltran J, Akdis C, et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma. Allergy. 2020;75(5):1023–1042. doi:10.1111/all.14221
- Kavanagh JE, Hearn AP, Dhariwal J, et al. Real-world effectiveness of benralizumab in severe eosinophilic asthma. Chest. 2021;159(2):496–506. doi:10.1016/j.chest.2020.08.2083
- Nagase H, Tamaoki J, Suzuki T, et al. Effectiveness of mepolizumab in severe asthma in Japan: a real-world study using claims data. Clin Transl Allergy. 2021;11(8):e12063. doi:10.1002/clt2.12063
- Kimura Y, Suzukawa M, Inoue N, Imai S, Akazawa M, Matsui H. Real-world benefits of biologics for asthma: exacerbation events and systemic corticosteroid use. World Allergy Organ J. 2021;14(11):100600. doi:10.1016/j.waojou.2021.100600
- Silver J, Bogart M, Packnett E, Wu J, McMorrow D, Hahn B. Real-world reductions in oral corticosteroid use in the USA following mepolizumab therapy for severe asthma. J Asthma Allergy. 2020;13:689–699. doi:10.2147/JAA.S275944
- Matsunaga K, Adachi M, Nagase H, Okoba T, Hayashi N, Tohda Y. Association of low-dosage systemic corticosteroid use with disease burden in asthma. NPJ Prim Care Respir Med. 2020;30(1):35. doi:10.1038/s41533-020-00192-x